Shares of Immunomedics Inc. plunged yesterday after the company said the Food and Drug Administration did not approve its product for colorectal cancer imaging. The stock closed at $3.50, down $2
Knowledgeable, collaborative team. VP Quality (Former Employee) - Morris Plains, NJ - November 15, 2018. Immunomedics is in a time of exciting development, and it is outstanding to see the hard work of the past 20 years pay off. The culture was one of highly competent research and collaborative excitement.